AllCells
Private Company
Funding information not available
Overview
AllCells, founded in 1998 and based in Alameda, California, is a critical supplier of human-derived biological materials for the life sciences industry. Operating as part of Discovery Life Sciences, it provides essential RUO and GMP-grade starting materials—such as leukopaks, bone marrow, and CD34+ stem cells—that are fundamental for advancing cell and gene therapy research and manufacturing. The company differentiates itself through a robust, recallable donor ecosystem, FDA-registered and GMP-adherent facilities, and industry-leading logistics, including rapid delivery times. Its services directly address supply chain bottlenecks, positioning it as a key enabler for complex therapy development from discovery through commercialization.
Technology Platform
Proprietary donor ecosystem with management software for reliable, recallable collections; State-of-the-art processing labs for high-viability/purity cell isolation; Integrated logistics for rapid delivery of fresh and cryopreserved products; GMP-compliant manufacturing for clinical-grade starting materials.
Opportunities
Risk Factors
Competitive Landscape
AllCells competes in the human biological products market with companies like STEMCELL Technologies, Lonza, and Charles River Laboratories' biospecimen units. Its differentiation lies in its specialized focus on hematological tissues, a robust donor management system ensuring high deliverability, and rapid logistics tailored for the fast-paced CGT sector.